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ABSTRACT 1 
Background: Full audiological monitoring is the best strategy to detect hearing loss early and 2 
to provide timely intervention in the absence of a clinical method of otoprotection. Full 3 
monitoring requires audiological evaluation before, and then during and after ototoxic cancer 4 
treatment. In a worldwide context of monitoring protocols that vary substantially, we 5 
analyzed the audiological monitoring of childhood cancer patients over the last decade across 6 
treatment centers in Switzerland.  7 
Procedure: We retrospectively searched for audiological evaluations in all nine Swiss 8 
Pediatric Oncology Centers. We analyzed proportions of patients who had audiological 9 
monitoring and described type and timing of monitoring. We determined predictors of 10 
audiological monitoring using multivariable logistic regression and described time trends. 11 
Results: We included 185 patients from the Swiss Childhood Cancer Registry diagnosed 12 
2005-2013 who had platinum chemotherapy and/or cranial radiation ≥30 Gray and who were 13 
alive at time of study. Less than half of children, 43%, had full audiological monitoring 14 
(before, during, and after treatment), while 72% were tested after cancer treatment. Non-study 15 
patients were less likely to have had monitoring in all phases of cancer treatment. Patients 16 
who received treatment with cisplatin or both platinum chemotherapy and cranial radiation 17 
were more likely to have had monitoring after treatment. Monitoring during and after 18 
treatment increased over the study period, but monitoring before treatment was insufficient in 19 
all time periods. 20 
Conclusions: Our population-based study indicates that audiological monitoring is 21 
insufficient in Switzerland, particularly for non-study patients. Clinicians’ must become more 22 
aware of the importance of full audiological monitoring.   23 
  
 
INTRODUCTION 24 
Platinum chemotherapy or/and cranial radiation can be toxic to the ear, a property called 25 
ototoxicity.1-3 Platinum can cause sensorineural hearing loss due to toxic levels of reactive 26 
oxygen species in the cochlea that damage hair cells, the stria vascularis, and spiral ganglion 27 
cells.1 Radiation ≥30 Gray (Gy) can cause sensorineural or conductive hearing loss due to 28 
direct damage to the external ear canal, the cochlea, the brainstem, or small vessels of the 29 
inner ear.1 High-frequency hearing loss is most common and may progress unnoticed until 30 
communication problems become apparent.1, 4 In children, moderate or even rather minimal 31 
hearing loss can impair speech development, cause learning problems, or reduce quality of 32 
life.5-9 It is, therefore, crucial that hearing loss is detected early. Clinicians might have the 33 
option to discuss whether cancer treatment can be modified, they can counsel patients and 34 
parents, offer hearing aids and thus mitigate the downstream effects of hearing loss. 35 
International guidelines10-14 and clinical studies (Supplementary Table S1) recommend 36 
audiological monitoring because no clinical method of otoprotection yet exists.15 Both the 37 
number of evaluations recommended and their timing vary substantially. However, all agree 38 
that full monitoring includes an initial audiological evaluation at baseline, before ototoxic 39 
treatment, to exclude any pre-existing hearing disorder; that evaluations should be repeated 40 
throughout the ototoxic treatment so that clinicians may modify cancer treatment; and that 41 
evaluation should continue after completion of cancer treatment to detect potential late-42 
manifesting hearing loss. Patients receiving only cranial radiation should be evaluated both 43 
before and after radiation of ≥30 Gy. However, no study has yet investigated whether 44 
clinicians adhere to these recommendations, and whether patient characteristics or cancer 45 
treatment predict monitoring, or if participation in a clinical study plays a role in monitoring.  46 
We characterized audiological monitoring in a national, registry-based sample of 47 
childhood cancer patients who received ototoxic cancer treatment. We analyzed predictors of 48 
  
 
audiological monitoring and evaluated whether audiological monitoring improved over the 49 
last decade.  50 
  
 
METHODS  51 
Study population 52 
The Swiss Childhood Cancer Registry (SCCR) is a nationwide, population-based registry 53 
that includes all children and adolescents residing in Switzerland who have been diagnosed 54 
with leukemia, lymphoma, central nervous system (CNS) tumors, malignant solid tumors, or 55 
Langerhans cell histiocytosis prior to the age of 21.16 Recent estimates indicate that the SCCR 56 
includes 91% of all patients diagnosed with cancer before the age of 16 in the years since 57 
1985, and about 95% of those diagnosed since 1995.17 The SCCR registers information on the 58 
diagnosis and treatment of the cancer and personal information. Tumors are classified 59 
according to the International Classification of Childhood Cancer, third edition (ICCC-3).18 60 
Ethics approval of analyses of SCCR data is granted by the Ethics Committee of the Canton 61 
of Bern to the SCCR (KEK-BE: 166/2014). 62 
Inclusion criteria 63 
We included all patients registered in the SCCR who were treated with ototoxic cancer 64 
treatment in the nine Swiss Pediatric Oncology Centers (Supplementary Fig. S1). We 65 
restricted the years of diagnosis to 2005-2013 because medical records from patients treated 66 
before 2005 are difficult to access due to Swiss data protection rules,19 and the treatment and 67 
follow-up of patients diagnosed after 2013 was not finished when data collection ended in 68 
December 2015. We assumed that audiological monitoring may not have been the first 69 
priority in treating terminally ill children, and excluded the records of children who were not 70 
alive at the time of study; in any event, their medical records were often not available.19 71 
We defined ototoxic cancer treatment as platinum chemotherapy or cranial radiation ≥30 72 
Gy according to the literature.11, 13, 14, 20, 21 To determine whether patients fulfilled the 73 
inclusion criteria, we obtained their personal and treatment-related information from the 74 
SCCR. 75 
  
 
Chart review 76 
We reviewed the medical records retrospectively. We collected audiological tests, the 77 
corresponding audiologists’ reports, oncological discharge reports, and cancer treatment 78 
protocols in all nine Swiss Pediatric Oncology Centers and the corresponding ear-nose-throat 79 
departments.  80 
Audiological monitoring  81 
Through the end of 2015, we collected all audiological tests that were performed as part of 82 
care before, during, and after cancer treatment, and recorded the type and timing of 83 
evaluation. We categorized type of audiological test as pure tone audiometry, extended high 84 
frequency audiometry, free field audiometry, auditory brainstem response, otoacoustic 85 
emissions (OAE) testing, speech audiometry, or tympanometry. To assess the timing of 86 
audiological evaluation, we categorized tests as before, during, and after treatment. We 87 
divided the extent of audiological monitoring into two categories: i) full audiological 88 
monitoring included patients with at least one evaluation at all stages (before, during, and 89 
after cancer treatment); and ii) minimal audiological monitoring included patients with one or 90 
more evaluation that occurred only after treatment. Patients with cranial radiation were 91 
defined as having had full audiological monitoring if they received at least one evaluation pre- 92 
and post-treatment. We graded the most recent hearing test for each ear separately and for 93 
frequencies up to 8 kHz according to the SIOP Boston Ototoxicity Scale, which is more 94 
sensitive to detect hearing loss than other ototoxicity scales.22, 23 We defined hearing loss as 95 
≥grade 1 (>20 dB above 4kHz) according to the SIOP Boston Ototoxicity scale in the most 96 
affected ear, and graded severity from 0 to 4.22 97 
Cancer treatment information 98 
We collected detailed patient information on cancer treatment from the SCCR, or from the 99 
clinic archives when it was not available in the SCCR. We recorded the name and arm of the 100 
  
 
clinical study, if applicable, the start and end dates of ototoxic cancer treatment, and dose of 101 
platinum chemotherapy or cranial radiation. We divided patients into three clinical study 102 
participation groups: patients officially registered in a clinical study; patients not registered in 103 
but treated according to a clinical study protocol (e.g., closed clinical study, study not open at 104 
the clinic); and patients who were treated but were neither registered in nor treated according 105 
to a study protocol. We classified patients into three ototoxic cancer treatment groups: cranial 106 
radiation ≥30 Gy, carboplatin, cisplatin, or both platinum chemotherapy and cranial radiation 107 
≥30 Gy. 108 
Statistical analysis 109 
We first determined how many children had had at least one audiological evaluation 110 
overall, and at least one evaluation before, during, or after cancer treatment. To investigate 111 
whether audiological monitoring varies between subgroups, we stratified for age at cancer 112 
diagnosis, ototoxic cancer treatment, clinical study participation, and hearing status at the last 113 
audiological evaluation. We then characterized the types of audiological tests used before, 114 
during, and after treatment, overall and stratified for age at cancer diagnosis. In a third step, 115 
we determined the number of evaluations patients had among those who received any 116 
monitoring, and described the length of audiological follow-up after ototoxic cancer 117 
treatment. We only considered patients with ≥5 years between last ototoxic treatment and 118 
time of study to have similar chances to be monitored among patients. The fourth step 119 
assessed predictors of audiological monitoring by using logistic regression models. We first 120 
compared patients who had full audiological monitoring to all who did not have full 121 
audiological monitoring, and then compared patients who had minimal audiological 122 
monitoring to those without any audiological monitoring. We used gender, age at cancer 123 
diagnosis, ototoxic cancer treatment, and clinical study participation as independent variables. 124 
Finally, we assessed time trends in audiological monitoring. We compared proportions of 125 
  
 
children who received audiological monitoring before, during, and after treatment between 126 
periods of cancer diagnosis, and tested for trends. To treat post-treatment differences with 127 
different lengths of follow-up equally, we considered only audiological evaluations within the 128 
first year after ototoxic treatment. We also used the Kaplan-Meier method to estimate 129 
cumulative incidence curves and calculated cumulative incidence for audiological monitoring 130 
12 months after treatment stratified by period of diagnosis. 131 
We used Stata (Version 13, Stata Corporation, Austin, Texas) for all analyses.  132 
  
 
RESULTS  133 
Characteristics of study population 134 
Among 1,916 children diagnosed 2005-2013 with cancer, 306 had potentially ototoxic 135 
treatment and of these 210 were alive and eligible for the study. The medical records of 14 136 
children were missing, and we excluded another 11 children who had been treated in 137 
Bellinzona, where both cancer care and follow-up are often shared with larger clinics and 138 
assessment of the complete medical records for a patient was not feasible. This resulted in 185 139 
patients whose records were available for analysis (Supplementary Fig. S1, Table 1). The 140 
mean age (SD) of these patients was 7 (5) years at diagnosis and 11 (6) years at the most 141 
recent audiological evaluation. Table 1 gives details on clinical characteristics and cancer 142 
treatment of the study population. Fifty-six patients (30%) had a pathological result in the 143 
most recent audiological evaluation, among whom 25 patients (13%)  had severity grade 1, 144 
while 21 patients (11%) had grade 2, 7 patients (4%) had grade 3, and 3 patients (2%) had 145 
grade 4. 146 
Proportion tested, and type of audiological tests  147 
Overall, 175 children (95%) treated with ototoxic cancer treatment had at least one 148 
evaluation, but only 78 children (42%) had full audiological monitoring in all phases of 149 
cancer treatment. Looking at each phase separately, 122 patients (66%) had at least one test 150 
before treatment, 125 (74%) were tested at least once during treatment, and 134 (72%) were 151 
tested one or more times after treatment (Table 2). Evaluation before treatment was more 152 
common in patients who were included in a clinical study or were treated according to a study 153 
protocol than in those whose treatment was not part of or conducted according to a study 154 
(73% and 64% respectively vs. 35%). Evaluation during treatment was less common in those 155 
younger than 5 years at diagnosis (60%), in those with carboplatin (61%), and in non-study 156 
patients (21%); and more common in patients older than 9 years at diagnosis (89%), in those 157 
  
 
with cisplatin (81%) or with both platinum chemotherapy and cranial radiation ≥30 Gy (77%), 158 
or in those officially included in a clinical study (82%). Evaluation after treatment was less 159 
common in patients with cranial radiation ≥30 Gy (56%), in those with carboplatin (51%), or 160 
in non-study patients (24%), but more common in those with cisplatin (85%) or both platinum 161 
chemotherapy and cranial radiation ≥30 Gy (81%). 162 
Pure tone audiometry, extended high frequency audiometry, and OAE testing were the 163 
most frequently used types of tests, independent of the time of treatment (Supplementary 164 
Table S2).  165 
Frequency of audiological evaluations and follow-up period 166 
Patients had in median one evaluation before, three during, or two after treatment (Table 167 
3). During treatment, tests were more frequent in patients with both platinum chemotherapy 168 
and cranial radiation ≥30 Gy (P<0.001). After treatment, tests were done more often in 169 
patients older than 9 years at diagnosis (P=0.020), in study patients (P=0.036) and in those 170 
who have developed hearing loss (P<0.001). Patients who received ototoxic cancer treatment 171 
five or more years ago had a median audiological follow-up of 29 months. The longest 172 
follow-up had those who received cranial radiation of ≥30 Gy (median 56 months, P=0.013). 173 
Predictors for full and minimal audiological monitoring 174 
Full audiological monitoring differed with clinical study participation (Table 4). Full 175 
monitoring was less common in non-study patients (adjusted OR 0.1). Only one out of 17 176 
children not treated according to a clinical study had full audiological monitoring. Minimal 177 
audiological monitoring differed with ototoxic cancer treatment and clinical study 178 
participation. It was more common in patients with cisplatin or both platinum chemotherapy 179 
and cranial radiation ≥30 Gy (adjusted OR 2.5, 1.5, respectively) and less common in non-180 
study patients (adjusted OR 0.2). Only four out of 17 children not treated according to a 181 
clinical study had minimal audiological monitoring. 182 
  
 
Time trends of audiological monitoring 183 
Proportions of patients with audiological monitoring changed over the last decade (Fig. 1). 184 
In 2005-2006, 55% had at least one evaluation before treatment. That proportion increased to 185 
79% in 2009-2010, but decreased back to baseline in 2013 (50%, P-trend=0.912). The 186 
proportion of patients with at least one evaluation during treatment increased from 68% in 187 
2005-2006 to 88% in 2013 (P-trend=0.045), and the proportion with at least one evaluation 12 188 
months after treatment increased from 42% in 2005-2006 to 60% in 2013 (P-trend=0.066). 189 
We found a nonsignificant trend towards an increasing cumulative incidence of auditory 190 
monitoring 12 months after treatment (P=0.059, Supplementary Fig. S2). Cumulative 191 
incidence of first audiological evaluation within 12 months after treatment was 45% (95% CI 192 
31-62%) in those diagnosed 2005-2006, 52% (95% CI 38-68%) in those diagnosed 2007-193 
2008, 60% (95% CI 45-74%) in those diagnosed 2009-2010, and 65% (95% CI 51-79%) in 194 
those diagnosed 2011-2012. Periods of diagnosis did not differ in age at diagnosis (P=0.666) 195 
or ototoxic cancer treatment (P=0.788).  196 
  
 
DISCUSSION 197 
This study of Swiss childhood cancer patients found that less than half of the children had 198 
full audiological monitoring that included an evaluation before, during, and after ototoxic 199 
cancer treatment. Seventy-two percent of study patients did receive at least one audiological 200 
evaluation after treatment, but non-study patients had significantly less audiological 201 
monitoring. Though monitoring during and after ototoxic treatment has become more frequent 202 
over the last decade, monitoring before treatment has been and remains insufficient. 203 
Evaluations before treatment provide a crucial reference for assessing hearing changes, and 204 
are needed for ototoxicity grading scales.10, 12, 24-26 They should therefore be as comprehensive 205 
as possible to have reference values for any evaluation conducted after ototoxic treatment. Yet 206 
in our study only 31 of 53 children (58%) at high risk to develop hearing loss from ototoxic 207 
therapy with platinum chemotherapy and cranial radiation had been monitored before 208 
treatment. Monitoring rates for baseline testing have been reported in other studies. Among 209 
seven oncologists and 16 audiologists in New Zealand who were interviewed to assess their 210 
knowledge of audiological monitoring of patients receiving potentially ototoxic treatment, all 211 
of the audiologists and six of the seven oncologists rated baseline evaluation as important.27 212 
Yet the clinicians had limited familiarity with guidelines, and their clinical practices varied, 213 
ranging from no routine monitoring to evaluations prior to each cycle of chemotherapy. A 214 
retrospective study in the U.S. found that hearing tests were performed at baseline in 71% of 215 
children with retinoblastoma treated under a Children’s Hospital of Philadelphia protocol.28 216 
However, in a study of children under the age of 18 who were treated for solid tumors with 217 
cisplatin and/or carboplatin according to SFOP protocols between 1987 and 1997 at the 218 
institute Gustave-Roussy in France, a low proportion of patients, 34 of 120 (28%), received an 219 
audiometric evaluation prior to the first course of treatment.29 These reports, as well as the 220 
  
 
paucity of such studies in the literature, reinforce our observation that evaluation before 221 
treatment falls well short of the need for it. 222 
Monitoring during treatment is specified by treatment protocols that have different 223 
monitoring schedules (Supplementary Table S1). For example, the Euramos protocol for 224 
osteosarcoma treatment used in 31 children in our study population suggested that only an 225 
evaluation before the 3rd and 4th cycle of cisplatin is needed. But, for 31 children treated 226 
according to HIT-2000, a protocol used to treat medulloblastoma, CNS PNET or 227 
ependymoma, monitoring was advised at each cycle of platinum chemotherapy. The protocol 228 
used to treat 10 children with medulloblastoma, ACNS0331, specified monitoring prior to 229 
every cisplatin cycle, which is in line with both American Academy of Audiology (AAA) and 230 
American Speech-Language-Hearing Association (ASHA) recommendations.10, 12 Overall, 231 
74% of our patients had at least one test during treatment. The percentage rose to 89% among 232 
patients who were older than 9 years, while 81% of those treated with cisplatin and 77% of 233 
those treated with both platinum chemotherapy and cranial radiation were tested at least once, 234 
as were 82% of those included in a clinical study. 235 
After ototoxic treatment, the St. Jude Children´s research hospital protocol recommends 236 
yearly evaluation up to 10 years after cancer treatment (Supplementary Table S1).30 However, 237 
the Children’s Oncology Group Long-Term Follow-Up Guidelines recommend monitoring 238 
only if impairment is detected after treatment.11 Variation across guidelines is by itself 239 
unlikely to explain why 28% of our patients received no evaluation after treatment. 240 
Participation in or treatment according to a clinical study improves monitoring. Thirteen of 241 
the 17 non-study patients received no post-treatment monitoring. Of these 17 non-study 242 
patients, 12 were diagnosed before the age of 5, 13 were diagnosed with retinoblastoma, and 243 
12 were treated solely with carboplatin. In Switzerland, institutional treatment protocols do 244 
not specify standardized protocols for audiological monitoring for retinoblastoma patients, 245 
  
 
and because carboplatin is less ototoxic clinicians may have performed fewer evaluations in 246 
this group.1, 3 However, international guidelines do not exclude children treated only with 247 
carboplatin, and particularly for patients with retinoblastoma development of an additional 248 
sensory handicap is crucial.31, 32 But conducting audiometry is challenging in this age group. 249 
Especially when young children are seriously ill, their cooperation and attention may be 250 
reduced, which can lead to hearing test results that have poor reliability, and to overall low 251 
testing rates.22 In all cases, though, audiological monitoring for several years after cancer 252 
treatment is important as hearing loss may only appear many years later particularly for 253 
patients treated with cranial radiation.3, 33 254 
Guidelines for audiological monitoring have changed over time. The 1994 ASHA 255 
guideline reported ototoxic effects only for platinum chemotherapy; audiological effects of 256 
cranial radiation were not well known at that time.10, 34 Fifteen years later, the AAA guideline 257 
recommended annual monitoring for one to two years after cranial radiation.12 Independent of 258 
monitoring schedules, evaluations themselves may be adjusted by, for example, focusing on 259 
the high frequencies that are critical in determining the onset of hearing loss.24 In the current 260 
St. Jude Children’s Hospital ototoxicity protocol, the number of evaluations depends on the 261 
platinum compound used or the dose of cranial radiation, but at least eleven hearing tests are 262 
recommended.30 It is therefore no surprise that audiological monitoring during and after 263 
treatment has increased since 2005, though monitoring before treatment has not. 264 
Our study was restricted to a retrospective review of charts from the clinics in which 265 
patients were treated for cancer. If any post-treatment evaluations were done in private 266 
practice our search would have missed them. To reduce this potential bias, we excluded 267 
patients treated in Bellinzona, a small clinic where identification of all medical documents 268 
was not feasible. With different guidelines recommending different numbers and timing of 269 
audiological evaluations, we simplified our definition of full audiological monitoring to 270 
  
 
encompass only a single evaluation at each treatment stage. We may have overestimated the 271 
adherence to monitoring guidelines, because we had no information on the indication for 272 
every audiological evaluation. Testings may have been done for indications other than 273 
ototoxicity monitoring (e.g. repeated ear infections). Another reason for an overestimation 274 
could be that childhood cancer patients who developed hearing loss may have received 275 
audiological evaluation not only for detection, but also for follow-up of hearing loss. We also 276 
did not have detailed information on type of radiation. Patients irradiated with protons thus 277 
may have received a lower dose to the auditory system and be at lower risk of developing 278 
hearing loss than those who had photon radiation therapy. Hearing loss can also occur after 279 
radiation with doses <30 Gy, but we only included patients who received cranial radiation ≥30 280 
Gy in the study population. Several studies suggest the cut-off of 30 Gy for ototoxicity.11, 20, 21 281 
We, therefore, expected clinicians to adhere to audiological monitoring guidelines only for 282 
those patients. Finally, our results cannot be extrapolated to children who died after cancer 283 
diagnosis. 284 
Our study does have several strengths. Using unique data from medical records to 285 
investigate audiological monitoring, we were able to include patients with different childhood 286 
cancer diagnoses and different treatment protocols. Having exact dates of ototoxic exposure 287 
and audiological evaluations enabled us to analyze the timing of monitoring in detail. We also 288 
considered children diagnosed 2005-2013, which allowed us to evaluate changes over time. 289 
Our results highlight how important it is to increase clinicians’ compliance with 290 
audiological monitoring guidelines. We suggest clinicians comply with either 291 
recommendations of clinical studies or more general recommendations like the ASHA 292 
guideline, especially for non-study patients in the absence of a study protocol for audiological 293 
monitoring. We believe that compliance with audiological monitoring recommendations 294 
would increase if different clinical studies and guidelines harmonize numbers and timing of 295 
  
 
audiological evaluations. The International Late Effects of Childhood Cancer Guideline 296 
Harmonization Group (www.ighg.org) is currently developing recommendations for 297 
ototoxicity monitoring after cancer treatment to unify existing recommendations and to 298 
provide optimum follow-up practices for audiological monitoring. This new guideline based 299 
on current literature, follow-up guidelines, and expert consensus will define who needs 300 
audiological monitoring, at what frequency, for how long, and what modality should be used. 301 
In summary, our study indicates that audiological monitoring guidelines are insufficiently 302 
followed in Switzerland, particularly when patients are neither participants in a study nor 303 
treated according to a specific study protocol. We need to increase clinicians’ knowledge of 304 
the importance of full audiological monitoring before, during, and after cancer treatment to 305 
increase compliance with international monitoring guidelines. Pediatric oncologists should be 306 
made aware of the need to send childhood cancer patients who will receive potentially 307 
ototoxic treatment to an audiologist for pretreatment monitoring. Standardized audiological 308 
monitoring that begins with a baseline evaluation is essential for the best possible audiological 309 
outcomes.   310 
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TABLE 1 Characteristics of the study population 
  N=185 (%) 
Gender  
Female 92 (50) 
Male 93 (50) 
Age at cancer diagnosis  
<5 year 73 (39) 
5-9 years 41 (22) 
10-16 years 71 (38) 
Period of cancer diagnosis  
2005-2006 38 (21) 
2007-2008 42 (23) 
2009-2010 42 (23) 
2011-2012 43 (23) 
2013 20 (11) 
Cancer diagnosis (ICCC-3)  
III: CNS tumor 72 (39) 
IV: Neuroblastoma 16 (9) 
V: Retinoblastoma 17 (9) 
VI: Renal tumor 7 (4) 
VII: Hepatic tumor 5 (3) 
VIII: Bone tumor 35 (19) 
IX: Soft tissue sarcoma 11 (6) 
X: Germ cell tumor 22 (11) 
Localisation  
Supratentorial 25 (14) 
Infratentorial 42 (23) 
Extracranial 25 (14) 
Intraspinal 13 (7) 
Others, not head 80 (43) 
Type of clinical studya  
SIOP 64 (35) 
GPOH & SFOP 75 (41) 
COG 50 (27) 
Clinical study participation  
Officially included in a clinical study 93 (50) 
Treated according to a clinical study 75 (41) 
Treated not according to a clinical study 17 (9) 
Platinum chemotherapy  
Cisplatin 98 (53) 
Mean (SD, range) dose in mg/m2 388 (141, 30-800) 
Carboplatin 92 (50) 
Mean (SD, range) dose in mg/m2 3,072 (2,874, 400-18,661) 
Cranial radiation 69 (37) 
Mean (SD, range) dose in Gy 56 (8, 40-77) 
Brain surgery  65 (35) 
Bone marrow transplantation  
No 171 (81) 
Yes 14 (11) 
Abbreviations: ICCC-3, International Classification of Childhood Cancer, Third edition; Gy, 
Gray; SIOP, International Society of Paediatric Oncology; COG, Children`s Oncology Group; 
GPOH, German Society of Paediatric Oncology and Haematology; SFOP, French Pediatric 
Oncology Society; SD, standard deviation.  
aCategories are not exclusive of each other: e.g., Euramos is included in COG and GPOH & 
SFOP. 
TABLE 2 Proportion of patients with audiological monitoring before, during and after ototoxic cancer treatment 
  Before treatment 
(n=185) 
 During treatmenta 
(n=169) 
 After treatment 
(n=185) 
  No AE ≥1 AE   No AE ≥1 AE   No AE ≥1 AE  
  n (%) n (%) P  n (%) n (%) P  n (%) n (%) P 
Overall  63 (34) 122 (66)   44 (26) 125 (74)   51 (28) 134 (72)  
Age at cancer diagnosis    0.143    0.001    0.102 
<5 year (n=73)  29 (40) 44 (60)   28 (40) 42 (60)   26 (36) 47 (64)  
5-9 years (n=41)  16 (39) 25 (61)   9 (25) 27 (75)   11 (27) 30 (73)  
10-16 years (n=71)  18 (25) 53 (75)   7 (11) 56 (89)   14 (20) 57 (80)  
Ototoxic cancer treatment    0.068    0.050    <0.001 
Cranial radiation ≥30 Gy (n=16)  5 (31) 11 (69)   -a -a   7 (44) 9 (56)  
Carboplatin (n=49)  21 (43) 28 (57)   19 (39) 30 (61)   24 (49) 25 (51)  
Cisplatin (n=67)b  15 (22) 52 (77)   13 (19) 54 (81)   10 (15) 57 (85)  
Platinum and cranial radiation ≥30 Gy (n=53)  22 (42) 31 (58)   12 (23) 41 (77)   10 (19) 43 (81)  
Clinical study participation    0.009    <0.001    <0.001 
Officially included in a clinical study (n=93)  25 (27) 68 (73)   15 (18) 70 (82)   23 (25) 70 (75)  
Treated according to a clinical study (n=75)  27 (36) 48 (64)   18 (26) 52 (74)   15 (20) 60 (80)  
Treated not according to a clinical study (n=17)  11 (65) 6 (35)   11 (79) 3 (21)   13 (76) 4 (24)  
Hearing loss at most recent audiological testingc    0.622    0.108    0.402 
No (n=115)  35 (30) 80 (70)   26 (25) 80 (75)   27 (23) 88 (77)  
Yes (n=56)  15 (27) 41 (73)   7 (13) 45 (87)   10 (18) 46 (82)  
Abbreviation: AE, audiological evaluation, P, P-value. 
aOnly 169 patients, those treated with platinum, could have had audiological monitoring during treatment because monitoring is not conducted 
during treatment with cranial radiation. 
bIncludes 7 patients who received both cisplatin and carboplatin. 
cHearing outcome was not available for 14 patients. 
TABLE 3 Frequency of audiological evaluations per patient (including only patients with at least one audiological evaluation) 
 Before 
treatment 
 During treatment After treatment Audiological follow-
up period in monthsd 
 Median 
(range) 
Pa  Median 
(range) 
Pa  Median 
(range) 
Std. 
Medianb 
Pc  Median 
(range) 
Pa 
Overall 1 (1-3)   3 (1-17)   2 (1-13) 0.33   29 (1-112)  
Age at cancer diagnosis  0.792   0.054    0.020   0.553 
<5 year (n=73) 1 (1-3)   2 (1-17)   2 (1-13) 0.28   41 (1-108)  
5-9 years (n=41) 1 (1-2)   4 (1-16)   2 (1-7) 0.33   25 (1-86)  
10-16 years (n=71) 1 (1-2)   3 (1-11)   2 (1-11) 0.42   28 (2-112)  
Ototoxic cancer treatment  0.295   <0.001    0.366   0.013 
Cranial radiation ≥30 Gy (n=16) 1 (1-1)   -f   2 (1-11) 0.44   56 (30-64)  
Carboplatin (n=49) 1 (1-2)   2 (1-17)   2 (1-4) 0.28   17 (1-108)  
Cisplatin (n=67)e 1 (1-3)   3 (1-6)   2 (1-13) 0.33   34 (1-112)  
Platinum and cranial radiation ≥30 Gy (n=53) 1 (1-2)   4 (1-9)   2 (1-11) 0.40   29 (2-86)  
Clinical study participation  0.603   0.420    0.036   0.834 
Officially included in a clinical study (n=93) 1 (1-3)   3 (1-17)   2 (1-13) 0.29   29 (1-112)  
Treated according to a clinical study (n=75) 1 (1-2)   3 (1-9)   2 (1-11) 0.40   30 (1-86)  
Treated not according to a clinical study (n=17) 1 (1-2)   1 (1-2)   1 (1-2) 0.20   8 (2-108)  
Hearing loss at most recent audiological testing  0.627   0.062    <0.001   0.281 
No (n=115) 1 (1-2)   3 (1-17)   2 (1-7) 0.29   27 (1-108)  
Yes (n=56) 1 (1-3)   3 (1-9)   4 (1-13) 0.47   39 (4-112)  
Abbreviations: Std, Standardized; P, P-value. 
aP-value derived from equality-of-medians test.  
bMedian is standardized for time between last ototoxic treatment and time of data collection. It shows the median number of audiological 
evaluations per year of follow-up. 
cP-value derived from standardized median using equality-of-medians test. 
dIncludes only patients with ≥5 years between last ototoxic treatment and time of study. 
eIncludes 7 patients who received both cisplatin and carboplatin. 
fOnly those treated with platinum, could have had audiological monitoring during treatment because monitoring is not conducted during treatment 
with cranial radiation. 
 
TABLE 4 Predictors of audiological monitoring in childhood cancer patients 
 Full audiological monitoring  
(≥1 audiological evaluation before, during, and 
after treatment) 
 (n=78) 
 Minimal audiological monitoring 
(≥1 audiological evaluation after treatment) 
(n=134) 
 n (%a) Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Pb  n (%c) Crude OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Pb 
Gender    0.404     0.928 
Female (n=92) 38 (41) 1.0 1.0   63 (68) 1.0 1.0  
Male (n=93) 39 (42) 1.0 (0.6-1.8) 0.8 (0.4-1.4)   71 (76) 1.5 (0.8-2.8) 1.0 (0.5-2.2)  
Age at cancer diagnosis    0.052     0.824 
<5 years (n=73) 24 (33) 1.0 1.0   47 (64) 1.0 1.0  
5-9 years (n=41) 13 (32) 0.9 (0.4-2.2) 0.7 (0.3-1.8)   30 (73) 1.5 (0.7-3.5) 1.0 (0.4-2.5)  
10-16 years (n=71) 40 (56) 2.6 (1.3-5.2) 1.9 (0.9-4.1)   57 (80) 2.3 (1.1-4.8) 1.3 (0.5-3.2)  
Ototoxic cancer treatment    0.495     0.031 
Cranial radiation ≥30 Gy (n=16) 7 (44) 1.0 1.0   9 (56) 1.0 1.0  
Carboplatin (n=49) 12 (24) 0.4 (0.1-1.4) 0.6 (0.2-2.1)   25 (51) 0.8 (0.3-2.5) 0.9 (0.3-3.2)  
Cisplatin (n=67)d 37 (55) 1.6 (0.5-4.8) 1.1 (0.3-3.7)   57 (85) 4.4 (1.3-14.6) 2.5 (0.7-9.1)  
Platinum and cranial radiation ≥30 Gy (n=53) 21 (40) 0.8 (0.3-2.6) 0.7 (0.2-2.5)   43 (81) 3.3 (1.0-11.1) 1.5 (0.7-3.3)  
Clinical study participation    0.006     0.010 
Officially included in clinical study (n=93) 48 (52) 1.0 1.0   70 (75) 1.0 1.0  
Treated according to clinical study (n=75) 28 (37) 0.6 (0.3-1.0) 0.6 (0.3-1.2)   60 (80) 1.3 (0.6-2.7) 1.5 (0.7-3.3)  
Treated not according to a clinical study (n=17) 1 (6) 0.1 (0.1-0.5) 0.1 (0.0-0.6)   4 (24) 0.1 (0.1-0.3) 0.2 (0.1-0.8)  
Abbreviation: P, p-value; OR, odds ratio; CI, confidence interval. 
aProportions of children with full audiological monitoring of the total number of children in the respective category.  
bP-value from multivariable regression using likelihood ratio test.  
cProportions of children with minimal audiological monitoring of the total number of children in the respective category.  
dIncludes 7 patients who received both cisplatin and carboplatin. 
Supplemental 
Supplementary TABLE S1 Recommendations for audiological monitoring 
 
Before 
treatment 
During treatment After treatment Minimal 
number of  
evaluations 
in total 
Grading scale Type of audiological test 
Clinical study protocola      
ACNS0331 for 
Medulloblastoma 
Yes Prior to every cycle 
with cisplatin 
Within 6 weeks of completion of 
chemotherapy, after 1 year, after 3 
years, annually after 3 years, obtain 
at 5 years only if clinically 
indicated 
6 CTCAE Audiometry (not further 
specified) 
HIT-2000 for 
Medulloblastoma/ 
CNS PNET/ 
Ependymoma 
Yes With each cycle of 
cis- or carboplatin, 
or radiotherapy (not 
specified whether 
before or after) 
Once per year for the first two 
years; following years, individually 
4 CTCAE Tone audiometry 
Euramos-1 for 
osteosarcoma 
Yes Prior 3rd and 4th AP 
cycle;  
after last cycle of 
chemotherapy 
Within 4 weeks after 
chemotherapy. If no impairment 
found it is possible to stop, but 
audiological monitoring is 
recommended until 10 years after 
end of therapy. 
5 CTCAE Audiometry (not further 
specified) 
Ototoxicity monitoring protocol      
ASHA 1994 Yes Prior to every cycle 
of platinum 
chemotherapy 
 
As soon as possible after treatment, 
3 and 6 months after platinum 
chemotherapy  
5 Not specified Pure tone audiometry including 
high frequencies, otoscopy, 
tympanometry, speech 
audiometry 
AAA 2009 Yes Prior to each cycle 
of platinum 
chemotherapy 
Few months after platinum 
chemotherapy 
Cranial radiation: annually 1-2 
years  
3 CTCAE, 
Brock´s 
hearing loss 
grades 
Baseline testing with all tests 
needed in subsequent evaluations: 
pure tone audiometry including 
high frequencies, tympanometry, 
speech audiometry, OAE testing 
 
Before 
treatment 
During treatment After treatment Minimal 
number of  
evaluations 
in total 
Grading scale Type of audiological test 
St. Jude Children´s 
research hospital 
ototoxicity protocol 
2013 
Yes Cisplatin: prior to 
every cycle  
Carboplatin: prior to 
every 2-4 cycles  
 
Platinum: at 3, 6, 9 and 12 months 
after treatment 
Cranial radiation: 
Low risk: annually for 5 years 
High riskb: every 6 months for 5 
years 
Follow both groups annually for 5 
additional years. 
Platinum: 
11 
 
 
Cranial 
radiation:  
Low risk: 
11 
High risk: 
16 
Not specified Baseline testing: Ototoscopy, 
tympanometry, pure tone 
audiometry including high 
frequencies, DPOAE testing, 
click and tone burst ABR/ASSR 
as indicated 
Long-term follow-up guideline      
Children’s Oncology 
Group 2013 
NA NA History for hearing difficulties, 
tinnitus, otoscopic exam yearly. 
Platinum: Baseline at entry into 
follow-up. If impairment is 
detected, test at least yearly. 
Cranial radiation ≥30 Gray: Yearly 
for 5 years after treatment (by 
patients < 10 years continue yearly 
until age 10), then every 5 years. 
If impairment is detected, test at 
least yearly. 
If inconclusive or unevaluable, 
consider OAE. 
NA as only 
follow-up is 
addressed 
Not specified Pure tone air and bone 
conduction, speech audiometry, 
and tympanometry for both ears. 
Frequency-specific auditory 
brainstem response can be 
performed if result is 
inconclusive.  
Dutch Childhood 
Oncology Group 
2010 
NA NA Cisplatin: every 5 years 
Carboplatin: initial screen 5 years 
after treatment, if no abnormalities 
detected, no repeat testing is 
required 
Cranial radiation ≥30 Gray: initial 
screen 5 years afterwards, if no 
Abnormalities detected, no repeat 
testing required 
NA as only 
follow-up is 
addressed 
Not specified Tone audiometry up to 12.5kHz 
and tympanometry 
 
Before 
treatment 
During treatment After treatment Minimal 
number of  
evaluations 
in total 
Grading scale Type of audiological test 
United Kingdom 
Children`s Cancer 
Study Group Late 
Effects Group 
2011 
NA NA After completion of treatment NA as only 
follow-up is 
addressed 
Not specified Pure tone audiogram. 
In infants: behavioral audiometry, 
otoacoustic emissions, or auditory 
brainstem responses. 
Abbreviations: AAA, American Academy of Audiology; ASHA, American Speech-Language-Hearing Association; AP-cycle, Doxorubicin-
Cisplatin cycle; ASCT, autologous stem cell transplantation; NA, not applicable; CNS, central nervous system; CTCAE, Common Terminology 
Criteria of Adverse Events; DPOAE, distortion product otoacoustic emission; ABR, auditory brainstem response; ASSR, auditory steady-state 
response.   
aWe described the recommendations of the three most frequently used clinical study protocols in the study population.  
b Cochlear exposure >35 Gray. 
 
  
 
 
 
Supplementary Figure S1 Flow chart of study population. 
aIncluding the following clinics: Kinderklinik Kantonsspital Aarau AG, Universitäts-
Kinderspital Basel, Universitäts-Kinderklinik Inselspital Bern, Ospedale S. Giovanni 
Bellinzona, Hospital des Enfants Geneve, CHUV Lausanne, Kinderklinik Kantonsspital 
Luzern, Ostschweizer Kinderspital St. Gallen, Universitäts-Kinderspital Zürich 
bOtotoxic cancer treatment defined as platinum chemotherapy or and cranial radiation ≥30 
Gray. 
 
.
Childhood cancer patients from the SCCR: 
diagnosed 2005-2013 in a Swiss Pediatric Oncology Centrea, treated with 
ototoxic cancer treatmentb and alive at study 
N=210 
Included in analysis 
n=185 
Medical records not found (n=14) 
Treated in Bellinzona (n=11) 
Supplementary TABLE S2 Type of audiological test, stratified by phase of ototoxic cancer treatment and age at diagnosis 
Type of audiological test per patient Before treatment  During treatment  After treatment 
Overall (n=185) n (%) max number 
of tests per 
patient 
  n (%) max number of 
tests per patient 
  n (%) max number 
of tests per 
patient 
 
Pure tone audiometry 62 (33) 2   67 (36) 16   83 (45) 11  
Extended high frequency audiometry 32 (17) 2   44 (24) 11   43 (24) 9  
Free field audiometry  18 (9) 3   22 (12) 15   23 (12) 11  
Auditory brainstem response 8 (4) 1   5 (3) 2   7 (4) 2  
OAE testing 31 (17) 2   37 (20) 15   33 (18) 3  
Speech audiometry 0 (0) 0   2 (1) 2   12 (6) 5  
Tympanometry 10 (5) 1   18 (10) 4   28 (15) 5  
Abbreviation: OAE, otoacoustic emissions  
Supplementary Figure S2 Cumulative incidence of first audiological evaluation after treatment. 
P-value derived from log-rank test to test for equivalence of incidence curves. 
We did not include patients diagnosed in 2013 as for some of those patients the period between the last ototoxic cancer treatment and the data 
collection was less than 12 months. 
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